8-K
filed May 27, 2026, 8:14 PM ET
ticker NMHI
CIK 0001947861
litigation
confidence high
sentiment negative
materiality 0.80
Nature's Miracle settles noteholder litigation for $575K; must reserve 222M shares
Nature's Miracle Holding Inc.
- Settles $791K asserted indebtedness on four convertible notes for $575K via cash and conversion rights.
- Cash payments: $50K due within 5 business days; $50K by June 15, 2026; $225K installment plan through Nov 15, 2026.
- Company must reserve 222,000,000 common shares for 1800 Diagonal and increase authorized capital by July 31, 2026.
- Court previously issued TRO and preliminary injunction; retains jurisdiction to enforce settlement.
- Default allows 1800 to seek full judgment and permanent injunctive relief for continued conversion.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001213900-26-061666
- form_type
- 8-K
- ticker
- NMHI
- cik
- 0001947861
- company_name
- Nature's Miracle Holding Inc.
- filed_at
- 2026-05-28T00:14:03+00:00
- discovered_at
- 2026-05-28T10:05:00.353209+00:00
- generated_at
- 2026-05-28T10:09:03.737090+00:00
- sec_items
- ["1.01", "9.01"]
- event_type
- litigation
- sentiment
- negative
- materiality_score
- 0.8
- calibrated_materiality_score
- 0.8
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001213900-26-061666
- json_url
- https://secwatch.observer/filing/0001213900-26-061666.json
- markdown_url
- https://secwatch.observer/filing/0001213900-26-061666.md
- text_url
- https://secwatch.observer/filing/0001213900-26-061666.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1947861/000121390026061666/0001213900-26-061666-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1947861/000121390026061666/ea0292392-8k_natures.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
OPY
Oppenheimer settles cash-sweep class action for $70M, to impact Q1 earnings
OPPENHEIMER HOLDINGS INC
April 27, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
MKTW
MarketWise settles arbitration with former CEO for $12.16M cash, redeems 520,867 units, terminates TRA rights
MARKETWISE, INC.
April 24, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
AGAE
Allied Gaming settles litigation with Knighted for ~$5.94M paid over 3 months; CEO Li personally guarantees payment
Allied Gaming & Entertainment Inc.
April 21, 2026, 7:59 PM ET
litigation
Items 1.01, 5.02, 8.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
ROIV
Roivant subsidiary Genevant settles LNP patent litigation with Moderna; includes license and payments
Roivant Sciences Ltd.
March 23, 2026, 7:59 PM ET
litigation
Items 1.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
OESX
Orion settles Voltrek earnout dispute for $3M cash; solar PPA exit adds $1.3M offset
ORION ENERGY SYSTEMS, INC.
March 20, 2026, 7:59 PM ET
litigation
Items 1.01, 8.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
TRNR
TRNR recovers $6.4M in full settlement of Sportstech loan dispute, ends legal proceedings
Interactive Strength, Inc.
March 5, 2026, 6:59 PM ET
litigation
Items 1.01, 8.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
ROIV
Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent
Roivant Sciences Ltd.
March 3, 2026, 6:59 PM ET
litigation
Items 1.01, 7.01, 8.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
ABUS
Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026
Arbutus Biopharma Corp
March 3, 2026, 6:59 PM ET
litigation
Items 1.01, 8.01, 9.01
same SEC item: 1.01, 9.01
same event type: litigation
similar materiality
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.